XGN · NASDAQ
Exagen (XGN) Stock Price & Fundamentals
Exagen (XGN) closed at $821.36 on Oct 9, 2026, up 0.10% from the previous close of $820.57.
Share price, past year
1Y +34.34%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $821.36 |
| Sep 30, 2026 | $841.76 |
| Aug 31, 2026 | $810.16 |
| Jul 31, 2026 | $786.75 |
| Jun 30, 2026 | $776.29 |
| May 29, 2026 | $781.32 |
| Apr 30, 2026 | $731.66 |
| Mar 31, 2026 | $730.31 |
| Feb 27, 2026 | $750.80 |
| Jan 30, 2026 | $714.15 |
| Dec 31, 2025 | $687.82 |
| Nov 28, 2025 | $659.45 |
| Oct 31, 2025 | $625.18 |
Key statistics
- Market cap
- $19.87B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.82
- Revenue (TTM)
- $71.12M
- Net income (TTM)
- −$18.92M
- Shares outstanding
- 24.2M
- Dividend yield
- —
- 52-week range
- $606.34 – $848.22
Exagen's market cap is $19.87B, based on a share price of $821.36 and 24.2M shares outstanding as of Jun 30, 2026.
Financials
Exagen reported revenue of $66.58M for fiscal 2025, up 19.65% from fiscal 2024.
Exagen reported a net loss of $19.95M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 8 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $66.58M | +19.7% | −$19.95M | −30.0% | −$0.93 | −$14.27M |
| FY2024ended Dec 31, 2024 | $55.64M | +5.9% | −$15.12M | −27.2% | −$0.83 | −$13.79M |
| FY2023ended Dec 31, 2023 | $52.55M | +15.3% | −$23.69M | −45.1% | −$1.34 | −$15.29M |
| FY2022ended Dec 31, 2022 | $45.56M | −5.7% | −$47.39M | −104.0% | −$2.77 | −$36.46M |
| FY2021ended Dec 31, 2021 | $48.30M | +15.1% | −$26.85M | −55.6% | −$1.68 | −$22.64M |
| FY2020ended Dec 31, 2020 | $41.98M | +3.9% | −$16.69M | −39.8% | −$1.32 | −$14.54M |
| FY2019ended Dec 31, 2019 | $40.39M | +24.5% | −$12.04M | −29.8% | −$8.46 | −$10.11M |
| FY2018ended Dec 31, 2018 | $32.44M | — | −$8.01M | −24.7% | −$293.34 | −$9.50M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $19.94M | −$3.20M | −$0.13 |
| Q1 FY2026ended Mar 31, 2026 | $17.31M | −$3.97M | −$0.17 |
| Q4 FY2025ended Dec 31, 2025 | $16.63M | −$4.67M | −$0.21 |
| Q3 FY2025ended Sep 30, 2025 | $17.24M | −$7.09M | −$0.31 |
| Q2 FY2025ended Jun 30, 2025 | $17.20M | −$4.44M | −$0.21 |
| Q1 FY2025ended Mar 31, 2025 | $15.50M | −$3.75M | −$0.20 |
| Q4 FY2024ended Dec 31, 2024 | $13.66M | −$3.76M | −$0.20 |
| Q3 FY2024ended Sep 30, 2024 | $12.51M | −$5.03M | −$0.28 |
Company profile
- Name
- Exagen Inc.
- Ticker
- XGN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Medical Laboratories
- Headquarters
- 1261 Liberty Way, Vista, CA 92081
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001274737
Recent SEC filings
- Aug 4, 2026
- Aug 4, 2026
- Jun 9, 2026
- May 11, 2026
- May 11, 2026
- Apr 23, 2026
- Mar 10, 2026
- Mar 10, 2026
Frequently asked questions
What is Exagen's stock price?
Exagen (XGN) closed at $821.36 on Oct 9, 2026, up 0.10% from the previous close of $820.57.
What is Exagen's market cap?
Exagen's market cap is $19.87B, based on a share price of $821.36 and 24.2M shares outstanding as of Jun 30, 2026.
How much revenue does Exagen make?
Exagen reported revenue of $66.58M for fiscal 2025, up 19.65% from fiscal 2024.
Does Exagen pay a dividend?
Exagen's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Exagen Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures